PMID

Data

Article Title

Organization

Recent Progress in Histone Demethylase Inhibitors.

University of Oxford

Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.

Glaxosmithkline

8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.

The Institute of Cancer Research

Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.

Glaxosmithkline

Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.

University of Oxford

Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.

University of Oxford

Recent Advances with KDM4 Inhibitors and Potential Applications.

St. Jude Children'S Research Hospital

Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).

Hangzhou Normal University

Discovery of Novel Pyrazole-Based KDM5B Inhibitor

Zhengzhou University

Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B).

Zhengzhou University

Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.

Zhengzhou University

Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.

Genentech

Identification of potent, selective KDM5 inhibitors.

Constellation Pharmaceuticals

Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.

Genentech

Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.

Kyoto Prefectural University of Medicine

C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.

Institute of Cancer Research

Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.

University of Oxford

Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.

Sapienza University of Rome

From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.

Genentech

In search of new a-glucosidase inhibitors: Imidazolylpyrazole derivatives.

University of The Punjab